Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3168512 | 0.82 | MEN1 (0.50) | BCHEALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL11265712 | 0.81 | MTNR1A (0.54) | BCHEALDH1A1CYP1A2CYP2D6MEN1 | |
| Hydrochloric Acid SCHEMBL2346825 | 0.80 | LMNA (0.55) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL11148402 | 0.80 | MCHR1 (0.57) | BCHECYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL9407510 | 0.79 | MEN1 (0.56) | BCHEALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL16264576 | 0.79 | MEN1 (0.56) | BCHEALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL2018449 | 0.79 | MEN1 (0.56) | BCHEALDH1A1CYP1A2CYP2D6MEN1 | |
| Hydrochloric Acid SCHEMBL21879620 | 0.78 | ALDH1A1 (0.58) | BCHEALDH1A1CYP1A2CYP2D6MEN1 | |
| Methoxymethane SCHEMBL10589288 | 0.77 | MEN1 (0.64) | BCHEALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL14629215 | 0.77 | MEN1 (0.44) | BCHEALDH1A1CYP1A2CYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023020457-A1 | PYRIDAZINONE OR PYRIDINONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-02-23 | — | — | WO | disclosed |
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8101751-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-24 | — | — | US | disclosed |
| US-8049008-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-11-01 | — | — | US | disclosed |
| US-7932384-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-04-26 | — | — | US | disclosed |
| US-20100240662-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-23 | — | — | US | disclosed |
| US-20100222303-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-02 | — | — | US | disclosed |
| US-20100120758-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-05-13 | — | — | US | disclosed |
| US-20100081655-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-04-01 | — | — | US | disclosed |
| US-7671054-B1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-02 | — | — | US | disclosed |
| US-20100029630-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | Chongwae Pharma Corporation (KR) | 2010-02-04 | — | — | US | disclosed |
| US-7585862-B2 | Colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss | CHOONGWAE PHARMA CORPORATION (KR) | 2009-09-08 | — | — | US | disclosed |
| US-7566711-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2009-07-28 | — | — | US | disclosed |
| US-7531320-B2 | Modulation of β-catenin/TCF-activated transcription | CHOONGWAE PHARMA CORPORATION (KR) | 2009-05-12 | — | — | US | disclosed |
| US-7232822-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-06-19 | — | — | US | disclosed |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-02-22 | — | — | US | disclosed |
| EP-0613458-A1 | ACYCLIC ETHYLENEDIAMINE DERIVATIVES AS SUBSTANCE P RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1994-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222303-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, WNT3, APC | BCHE 3478/4885ALDH1A1 3409/4885CYP1A2 4403/4885 |
| US-20100029630-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | BCHE 4032/4885ALDH1A1 4305/4885CYP1A2 4837/4885 |
| US-20100120758-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | BCHE 4032/4885ALDH1A1 4305/4885CYP1A2 4837/4885 |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | BCHE 4032/4885ALDH1A1 4305/4885CYP1A2 4837/4885 |
| US-20100081655-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | BCHE 4032/4885ALDH1A1 4305/4885CYP1A2 4837/4885 |
| US-20100240662-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, WNT3, APC | BCHE 3478/4885ALDH1A1 3409/4885CYP1A2 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.